MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations
Analyst Recommendations on GILEAD SCIENCES
10/18GRAPHIC - TAKE FIVE : Super Saturday, Super Mario
RE
10/15New Gilead Sciences CFO Expected to Pursue More Deals to Expand Portfolio
DJ
08/22GSK's long acting HIV injection gets boost from study
RE
08/07ASSEMBLY BIOSCIENCES : Shares Rise as Gilead Vet Takes Helm
DJ
07/30GILEAD SCIENCES : Posts Higher 2Q Earnings, Sales
DJ
07/16GSK's two-drug HIV Dovato treatment meets main goal in study
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15Gilead to Expand Its Bet on Research -- WSJ
DJ
07/14Gilead to Boost Stake in Belgian Biotech Galapagos as Part of $5.1 Billion De..
DJ
07/14Gilead to Boost Stake in Belgian Biotech Galapagos as Part of $5.1 Billion De..
DJ
05/02GILEAD SCIENCES : Correction to Gilead Sciences Article
DJ
05/02GILEAD SCIENCES : Reports 28% Increase in Net Income
DJ
05/02GILEAD SCIENCES : Reports Q1 Results Above Wall Street Targets
DJ
05/02GLOBAL MARKETS LIVE : Boeing, Apple, Fiat Chrysler, Bayer…
04/08GSK wins U.S. nod for two-drug HIV combination
RE
02/04GILEAD SCIENCES : Struggling to Revamp Sales, Projects Another Annual Sales Decl..
DJ
01/30GILEAD SCIENCES, INC. : annual earnings release
2018Gilead Sciences snares Roche veteran O'Day as CEO
RE
2018GILEAD SCIENCES : Raises Annual Product-Sales Forecast Following Earnings Beat
DJ
2018GILEAD SCIENCES, INC. : quaterly earnings release
2018GILEAD SCIENCES : to Slice List Prices of Liver Drugs -- 2nd Update
DJ
2018GILEAD SCIENCES : to Slice List Prices of Liver Drugs -- Update
DJ
2018U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -- Update
DJ
2018U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite Discount
DJ
2018Galapagos, Gilead bask in $4-6 billion new drug sales hope
RE
2018Amgen profit beats Street view, will not raise prices again in 2018
RE
2018GILEAD SCIENCES : CEO Stepping Down -- Update
DJ
2018GILEAD SCIENCES, INC. : half-yearly earnings release
2018GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
2018GILEAD SCIENCES : Quarterly Results Miss Wall Street Expectations -- Earnings Re..
DJ
2018GILEAD SCIENCES, INC. : quaterly earnings release
2018Currency and pricing squeeze GSK as new shingles vaccine shines
RE
2018GlaxoSmithKline prescribes commercial reboot for pharma division
RE
2018GlaxoSmithKline prescribes commercial reboot for pharma division
RE
2018SANGAMO THERAPEUTICS : Surges on Therapy Collaboration Deal with Kite -- Market ..
DJ
2018Sangamo in $3 billion gene-editing deal with Gilead
RE
2018FTSE slides after BOE meeting as pound pops higher
RE
2018GlaxoSmithKline sees light at end of Advair tunnel
RE
2018GILEAD SCIENCES : Reports Quarterly Loss Driven by Tax Charge -- Earnings Review
DJ
2018GILEAD SCIENCES, INC. : annual earnings release
2017Pfizer expects broad interest for consumer health business
RE
2017MARKET SNAPSHOT : Stock Market Climbs As Tech Rally Powers Gains
DJ
2017MARKET SNAPSHOT : Stock Market Climbs As Tech Rally Powers Gains
DJ
2017MARKET SNAPSHOT : S&P 500, Nasdaq Climb After Stronger-than-expected GDP, Hot Te..
DJ
2017GILEAD SCIENCES : Looks Away From Hepatitis C Treatments for Growth
DJ
2017GILEAD SCIENCES : Bets $11 Billion On New Cancer Therapy -- WSJ
DJ
2017GILEAD SCIENCES : to Buy Kite Pharma for Roughly $11 Billion -- 2nd Update
DJ
2017GILEAD SCIENCES : to Buy Kite Pharma for Roughly $11 Billion -- Update
DJ
2017GILEAD SCIENCES : to Buy Kite Pharma for Roughly $11 Billion in Cash
DJ
2017GILEAD SCIENCES, INC. : half-yearly earnings release
2017One of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
DJ
2017GILEAD SCIENCES : and GSK go head-to-head with similar HIV drug data
RE
2017New GlaxoSmithKline CEO wants fewer, bigger new drug launches
RE
2017Gilead challenges GSK with strong HIV drug data
RE
2017Weak pound buoys GSK but drugmaker warns on 2017 generic threat
RE
2017GILEAD SCIENCES : Posts Profit, Revenue Declines -- Update
DJ
2017Gilead Posts Profit, Revenue Declines
DJ
2017New GlaxoSmithKline CEO prepares for R&D choices, potential deals
RE
2017AbbVie's revenue miss clouds strong Humira U.S. sales
RE
2016GILEAD SCIENCES : Sales of Hepatitis C Drugs Harvoni and Sovaldi Slump Under Com..
DJ
2016MERCK : Profit Rises on Cancer Drugs, Vaccines
DJ
2016Deal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
DJ
2016Pfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
DJ
2016Merck Revenue Rises on Cancer, Hepatitis Treatments
DJ
2016MERCK : Revenue Rises on Cancer, Hepatitis Treatments
DJ
2016GILEAD SCIENCES : cuts 2016 sales forecast, cites hepatitis C drugs
RE
2016GILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 2nd Update
DJ
2016GILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 3rd Update
DJ
2016GILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- Update
DJ
2016GILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19%
DJ
2016Gilead Sales of Hepatitis C Drugs Fall 19%
DJ
2016GILEAD SCIENCES : Names New Operating Chief
DJ
2016MERCK : Revenue Falls on Generic Competition
DJ
2016GILEAD SCIENCES : Reports Drop in Hepatitis C Drug Revenue -- Update
DJ
1  2  3  4Next
Official Publications
08/29Report 
08/23SEC Filing 8K 
08/20Report 
08/13Report 
07/30Dividends 
07/30Dividends 
Upcoming event on GILEAD SCIENCES